Introduction {#s1}
============

Artemisinin combination therapy (ACT), the frontline treatment for *P. falciparum* infection, has played a major part in reducing the number of deaths due to malaria over the past decade ([@bib53]). However the increasing prevalence of artemisinin resistant *P. falciparum* across large parts of Southeast Asia threatens to destabilise malaria control worldwide ([@bib9]; [@bib20]; [@bib42]; [@bib25]; [@bib3]; [@bib52]). One of the main contemporary challenges in global health is to prevent artemisinin resistance from becoming established in Africa, where the consequences for childhood mortality could be disastrous ([@bib10]).

Understanding the epidemiological and evolutionary driving forces behind artemisinin resistance is essential to develop effective strategies to stop it spreading. At the molecular level, artemisinin resistance is caused by mutations in a kelch protein encoded by PF3D7_1343700 on *P. falciparum* chromosome 13, referred to here as *kelch13*. More specifically, non-synonymous mutations in the *kelch13* propeller and BTB-POZ domains (KPBD) result in reduced sensitivity of *P. falciparum* to artemisinin, as demonstrated by multiple lines of evidence including laboratory studies of artificially acquired resistance, genetic association studies of natural resistance and allelic replacement experiments ([@bib2]; [@bib15]; [@bib35]; [@bib46]; [@bib47]). Parasites with KBPD mutations tend to grow more slowly in the early part of the erythrocytic cycle, and have an enhanced unfolded protein response, both of which might act to protect against oxidative damage caused by artemisinin ([@bib8]; [@bib37]). It has also recently been shown that the *PI3K* protein is the target of artemisinin action, and that *kelch13* binds to *PI3K* to mark it for degradation; by affecting this binding, KBPD mutations result in high levels of *PI3K* which counteract the effect of artemisinin ([@bib32]).

A striking characteristic of the current distribution of artemisinin resistance is that it is caused by multiple independent KPBD mutations emerging in different locations, i.e. it does not originate from a single mutational event. More than 20 KPBD SNPs have been associated with delayed parasite clearance during artemisinin treatment and there are several documented instances of the same allele arising independently in different locations ([@bib3]; [@bib35]; [@bib47]). These are classic features of a soft selective sweep which, according to evolutionary theory, is most likely to arise in populations where the selected alleles are already present as standing genetic variations or have been repeatedly introduced by *de novo* mutations ([@bib19]; [@bib41]; [@bib33]). There is ongoing debate among evolutionary biologists about how commonly soft selective sweeps occur in nature ([@bib22]; [@bib14]) but they have clearly played a role in previous forms of antimalarial drug resistance ([@bib39]; [@bib44]) and the current epidemic of artemisinin resistance is the most extreme example of a soft selective sweep thus far observed in eukaryotes.

This creates a practical problem in monitoring the global spread of resistance. Artemisinin resistance can be measured directly, by following the rate of parasite clearance in patients ([@bib12]) or by testing parasite isolates in vitro ([@bib51]), but these phenotypic assays are resource intensive and impractical for large-scale screening in resource-poor settings. Genetic approaches are therefore preferable for practical implementation of large-scale surveillance, but the soft selective sweep of artemisinin resistance produces much more heterogeneous genetic signatures than previous global waves of chloroquine and pyrimethamine resistance, where hard selective sweeps were the dominant mode of spread. Thus there is considerable uncertainty about the epidemiological significance of the growing number of non-synonymous KPBD mutations reported in Africa ([@bib3]; [@bib21]; [@bib24]; [@bib49]). Previous studies in Africa have not identified variants known to cause resistance in Southeast Asia ([@bib24]; [@bib49]). At the same time, there are documented instances of African parasites that can be rapidly cleared by artemisinin treatment, although they carry KPBD mutations ([@bib3]). In the absence of comprehensive phenotypic data, it is not known which of these mutations, if any, are markers of resistance. This is a limitation of conventional molecular epidemiology, which tracks specific mutations and haplotypes and is poorly equipped to monitor soft selective sweeps where new mutations are continually arising on different haplotypic backgrounds, making it difficult to keep track of their phenotypic effects and evolutionary trajectories.

Here we explore how genomic data might help overcome these practical obstacles to monitoring the current epidemic of artemisinin resistance. This analysis includes genome sequencing data for 3,411 clinical samples of *P. falciparum* obtained from 43 locations in 23 countries. This large dataset was generated by the MalariaGEN *Plasmodium falciparum* Community Project, ([www.malariagen.net/projects/parasite/pf](www.malariagen.net/projects/parasite/pf)), a collaborative study in which multiple research groups working on different scientific questions are sharing genome variation data to generate an integrated view of polymorphism in the global parasite population. Data resources arising from the present analysis, including genotype calls and sample metadata, can be obtained at [www.malariagen.net/resource/16](www.malariagen.net/resource/16). The MalariaGEN Plasmodium falciparum Community Project also developed a user-friendly web application, with interactive tools for exploring and querying the latest version of the data: [www.malariagen.net/apps/pf](www.malariagen.net/apps/pf).

Results {#s2}
=======

Africa and Southeast Asia both have many *kelch13* polymorphisms {#s2-1}
----------------------------------------------------------------

Paired-end sequence reads were generated using the Illumina platform and aligned to the *P. falciparum* 3D7 reference genome, applying a series of quality control filters as previously described (see Materials and methods) ([@bib31]; [@bib34]). The initial alignments identified 4,305,957 potential SNPs, which after quality control filtering produced a set of 935,601 exonic SNPs that could be genotyped with high confidence in the majority of samples, and that form the basis for the current analysis.

As summarised in [Table 1](#tbl1){ref-type="table"}, the dataset comprised 1,648 samples from Africa and 1,599 samples from Southeast Asia, allowing us to compare these two groups directly without the need for sample size corrections. We identified a total of 155 SNPs in the *kelch13* gene, of which 128 were seen in Africa and 62 in Southeast Asia ([Table 2](#tbl2){ref-type="table"}). Studies in Southeast Asia have found that artemisinin resistance is associated with non-synonymous polymorphisms in the KPBD. Out of a total of 46 non-synonymous SNPs in these domains we found a similar number in Africa (n = 26) and Southeast Asia (n = 34), with 14 seen in both places ([Table 3](#tbl3){ref-type="table"}). Seven of those observed in Africa have previously been associated with artemisinin resistance in Southeast Asia, including C580Y, the most common allele in resistant parasites ([@bib35]).10.7554/eLife.08714.003Table 1.Count of samples analysed in this study.**DOI:** [http://dx.doi.org/10.7554/eLife.08714.003](10.7554/eLife.08714.003)RegionCodeSample countsCountryCodeSample countsWest AfricaWAF957Burkina FasoBF56CameroonCM134GhanaGH478Gambia, TheGM73GuineaGN124MaliML87NigeriaNG5East AfricaEAF412KenyaKE52MadagascarMG18MalawiMW262TanzaniaTZ68UgandaUG12Central AfricaCAF279D. R. CongoCD279South AmericaSAM27ColombiaCO16PeruPE11South AsiaSAS75BangladeshBD75West Southeast AsiaWSEA497MyanmarMM111ThailandTH386East Southeast AsiaESEA1102CambodiaKH762LaosLA120VietnamVN220OceaniaOCE62Indonesia (Papua)ID17Papua New GuineaPG4510.7554/eLife.08714.004Table 2.Worldwide distribution of *kelch13* mutations. Number of *kelch13* propeller and BTB-POZ domain (KPBD) mutations present (not necessarily exclusively) in 5 populations (AFR = Africa, SEA = Southeast Asia, SAS = South Asia, OCE = Oceania, SAM = South America). Sample size is reported for each population.**DOI:** [http://dx.doi.org/10.7554/eLife.08714.004](10.7554/eLife.08714.004)AFR\
(N = 1,648)SEA\
(N = 1,599)SAS\
(N = 75)OCE\
(N = 62)SAM\
(N = 27)Non-synonymousKPBD2634110Upstream region4216211SynonymousKPBD389100Upstream region22310010.7554/eLife.08714.005Table 3.List of non-synonymous KPBD mutations. Non-synonymous mutations found in the *kelch13* propeller and BTB-POZ domains (KPBD) and their position on chromosome Pf3D7_13_v3. For each mutation is reported where it has been observed and in how many samples. Where known, we reported if the mutation has been previously observed in patients with a prolonged parasite clearance half-life (\>5 hr) by Miotto et al. 2014 and/or Ashley et al 2014. Sample size is reported for each population.**DOI:** [http://dx.doi.org/10.7554/eLife.08714.005](10.7554/eLife.08714.005)MutationGenomic coordinatesAFR\
(N = 1,648)SEA\
(N = 1,599)SAS\
(N = 75)OCE\
(N = 62)SAM\
(N = 27)Observed in ART-R samples?D353Y1725941-4\-\--YesF395Y1725814-1\-\--NoI416V172575211\-\--I416M17257501\-\-\--K438N1725684-1\-\--NoP441L1725676-27\-\--YesP443S1725671-1\-\--F446I1725662-7\-\--YesG449A1725652-7\-\--YesS459L172562222\-\--A481V1725556-4\-\--YesS485N1725544-1\-\--Y493H1725521176\-\--YesV520I17254401\-\-\--S522C172543421\-\--YesP527H172541815\-\--C532S17254041\-\-\--V534L17253982\-\-\--N537I172538811\-\--NoG538V1725385-19\-\--YesR539T1725382-63\-\--YesI543T1725370-34\-\--YesP553L1725340224\-\--YesA557S17253291\-\-\--R561H1725316124\-\--YesV568G1725295-6\-\--YesT573S17252802\-\-\--P574L1725277-12\-\--YesR575K1725274-3\-\--A578S172526618\-\-\--NoC580Y17252592423-1-YesD584V1725247-3\-\--YesV589I17252332\-\-\--T593S17252211\-\-\--E612D17251621\-\-\--Q613E172516151\-\--Q613L17251601\-\-\--NoF614L1725158-1\-\--NoY630F172510921\-\--V637I17250892\-\-\--P667A1724999-2\-\--P667L1724998-21\--F673I1724981-3\-\--YesA675V1724974118\-\--YesA676S172497223\-\--H719N172484318\-\--Yes

*kelch13* polymorphisms in Africa appear to be indigenous {#s2-2}
---------------------------------------------------------

We asked whether *kelch13* polymorphisms seen in Africa had emerged independently, as opposed to migrating from Southeast Asia. We started by grouping samples according to genome-wide genetic similarity, based on a neighbour-joining (NJ) tree ([Figure 1A](#fig1){ref-type="fig"}). African and Southeast Asian samples formed two well-separated and distinct clusters, suggesting that gene flow between the two regions is very modest or negligible, a view supported by an alternative analysis using principal coordinate analysis ([Figure 1B](#fig1){ref-type="fig"}). None of the African parasites carrying *kelch13* mutations grouped with the Southeast Asian population, supporting the idea that these mutations are indigenous.10.7554/eLife.08714.006Figure 1.Differentiation between African and Asian genomes.(**A**) Neighbour-joining tree showing population structure across all sampling sites, with sample branches coloured according to country groupings ([Table 1](#tbl1){ref-type="table"}). Branches with large open tip circle indicate the sample is a *kelch13* mutant, while those with a small black symbol are mixed infections (i.e. mixture of wild-type and mutant parasites or two mutant parasites with different mutations). Branches without tip symbols are *kelch13* wild type. African *kelch13* mutants are, at a genomic level, similar to other African samples. (**B**) Plot of second principal component (PC2) against the first (PC1), computed from a principal coordinate analysis (PCoA) of all samples in the present study, based on the same pairwise genetic distance matrix used for the tree of [Figure 1A](#fig1){ref-type="fig"}. PC1 clearly separates African samples from those collected in SEA, while PC2 is mainly driven by extreme population structure in ESEA.**DOI:** [http://dx.doi.org/10.7554/eLife.08714.006](10.7554/eLife.08714.006)

We considered that recombination between African and imported parasites could result in the transfer of DNA segments of Asian origin into genomes that otherwise appear to be local, and therefore not be easily detectable through genome-wide analysis. Thus, we analyzed the regions immediately flanking *kelch13* in both directions, using a probabilistic method to reconstruct the most likely geographical origin of haplotypes observed in African *kelch13* mutants ([Figure 2](#fig2){ref-type="fig"}). The vast majority of *kelch13* mutants showed no evidence that flanking regions may have been imported, which indicates that most mutations observed in Africa do not have a common origin with those in Asia, and are likely to have emerged independently on a variety of haplotypes ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).10.7554/eLife.08714.007Figure 2.Local origin of African *kelch13* mutations.(**A**) Chromosome painting (see Materials and methods) of the 52 African *kelch13* mutants across the two 250 kbp flanking regions on each side of the *kelch13* gene. Each genome chunk is coloured according to the aggregated posterior probabilities that it originated in the African (red) or SEA (blue) population, according to the scale shown. (**B**) Detail of the flanking regions over a span of approximately 15 kbp, using the same colour scheme. The country of origin is indicated on the left, followed by the proportion of African chunks identified; the *kelch13* mutation carried by the sample is shown on the right. Samples are sorted by the proportion of Asian chunks in this window, and the same order was applied to Panel A. Only five samples (lower region of the panel) show strong probability of Asian origin of the chunks closest to *kelch13*.**DOI:** [http://dx.doi.org/10.7554/eLife.08714.007](10.7554/eLife.08714.007)10.7554/eLife.08714.008Figure 2---figure supplement 1.Diversity within *kelch13*-flanking haplotypes in African mutants.Using the same SNPs utilized in the analysis shown in [Figure 2B](#fig2){ref-type="fig"}, we estimated diversity in a 1 kbp sliding window around *kelch13* (highlighted in grey), by computing the mean SNP heterozygosity in a random set of 56 African *kelch13* wild type genomes. The blue shaded area reports 95% of the distribution of the values over 1000 iterations. We also computed the heterozygosity estimate for the set of 56 African *kelch13* mutants (red line), and found it not to be significantly different from those in wild-type parasites, suggesting that no common flanking haplotype is shared among these mutants.**DOI:** [http://dx.doi.org/10.7554/eLife.08714.008](10.7554/eLife.08714.008)10.7554/eLife.08714.009Figure 2---figure supplement 2.Origin of flanking haplotypes in selected African *kelch13* mutants.Here, chromosome painting is applied to the 15 kbp region around the *kelch13* gene (as in [Figure 2B](#fig2){ref-type="fig"}) for five samples for which *kelch13* was flanked by chunks with \>50% probability of Asian origin. Here, the SEA population was divided into two groups: *kelch13* wild type (blue) and mutants (yellow), to estimate the likelihood that the haplotype originated in SEA *kelch13* mutants. Strong evidence of origin from SEA mutants was only found in two samples: Y483H mutant from Ghana (top row), and a C580Y mutant from Cameroon (bottom row).**DOI:** [http://dx.doi.org/10.7554/eLife.08714.009](10.7554/eLife.08714.009)

Only 5 samples out of 56 were assigned a significant probability of Southeast Asian origin in at least one flanking sequence, and only two of these samples carried haplotypes similar to those in SEA mutants ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Both in the NJ tree and in the PCA, these two African *kelch13* mutants do not cluster with the bulk of African samples, but occupy a somewhat isolated position ([Figure 1](#fig1){ref-type="fig"}). We note that they exhibit unusually high levels of heterozygosity (F~WS~ \< 0.4), with mixed calls randomly distributed across the genome, consistent with a mix of African and SEA parasites. Continuous genetic monitoring of the parasite population will determine whether these are indeed just isolated cases, or they constitute very early evidence of gene flow between the two regions. Since these samples passed through a number of different laboratories, we cannot absolutely rule out the possibility that these mixtures could be the result of biological contamination during sample preparation and processing.

Across the genome there are many more rare variants in Africa {#s2-3}
-------------------------------------------------------------

Historical demographic changes such as population expansions and bottlenecks ([@bib48]), and epidemiological and environmental factors ([@bib43]) are highly influential forces that shaped the allele frequency spectra of *P. falciparum* populations across the globe ([@bib40]; [@bib31]). In order to properly contextualize the numbers and frequencies of *kelch13* mutations, it is therefore important to characterize genomic variation patterns in different geographical regions.

One of the most striking features of this dataset is the high number of rare variations in the high-quality SNP list. At more than half of all polymorphic sites, the minor allele was only carried by a single sample (referred to as *singletons*, n = 330,783 or 35%) or by two samples (*doubletons*, n = 214,179 or 23%), often in heterozygous calls. By contrast, only 13,383 polymorphisms (1.4%) had a minor allele in ≥5% of samples. Rare alleles, however, are not evenly distributed geographically. There is a large excess of polymorphisms with minor allele frequency (MAF) below 0.1% in Africa (71% of all SNPs, vs. 17% in SEA), while numbers in the two regions are similar for SNPs with MAF\>1% (2% of all SNPs, [Figure 3a](#fig3){ref-type="fig"}). Rare variations in Africa are not confined to a limited set of highly variable genes, but evenly distributed across the genome, as attested by the distribution of variants across all genes: SNP density in Africa (median = 67 SNPs/kbp, interquartile range = 51--84) is approximately 3.9 times higher than in SEA (median = 17, IQR = 13--22, p \< 10^--16^, [Figure 3b](#fig3){ref-type="fig"}). Very similar ratios are estimated in both non-synonymous (Africa median SNP density = 43, IQR = 27--58; SEA median = 11, IQR = 7--15) and synonymous variants (Africa median SNP density=25, IQR = 20--30, SEA median = 6, IQR = 4--8). Accordingly, we found virtually identical distributions of the ratio of non-synonymous to synonymous mutations (N/S ratio) in the two regions ([Figure 3c](#fig3){ref-type="fig"}). This suggests that the huge disparity in SNP density between the two regions is more likely to be the result of different demographic histories and epidemiological characteristics, such as changes in effective population size ([@bib23]), rather than the product of different selective constraints.10.7554/eLife.08714.010Figure 3.Number and density of variants in Africa and Southeast Asia.(**a**) Allele frequency spectrum for Africa (red) and SEA (blue). Polymorphisms were binned by their minor allele frequency (MAF), and the counts in each bin were plotted against frequency, shown on a logarithmic scale. Although the number of high-frequency variations is consistent between the two regions, samples from Africa possess an excess of low-frequency variations. (**b**) SNP density per gene: for each gene, the number of variants found in the two regions is normalized by the length of the coding region (in kbp). African samples have on average 3.9 times more mutations than parasites from SEA. (**c**) Non-synonymous/synonymous ratio per gene: ratios of non-synonymous to synonymous mutations found per gene are similar in the two regions. To reduce artifacts due to small numbers, only genes with at least 10 SNP were considered in both analyses.**DOI:** [http://dx.doi.org/10.7554/eLife.08714.010](10.7554/eLife.08714.010)10.7554/eLife.08714.011Figure 3---figure supplement 1.Site frequency spectrum for non-synonymous mutations in the KPBD.Allele frequency spectra for Africa (red) and SEA (blue) of non-synonymous mutations in the KPBD. Polymorphisms were binned by their minor allele frequency (MAF), shown on a logarithmic scale, and the counts in each bin reported. The two populations exhibit dramatically different behaviours with an abundance of medium and high frequency variations in SEA contrasted by an extreme paucity in Africa.**DOI:** [http://dx.doi.org/10.7554/eLife.08714.011](10.7554/eLife.08714.011)

In summary, we observe many more rare variants in Africa than in SEA; however we expect N/S ratios to be similar in these two regions in genes that are not subjected to selective pressures.

Comparing *kelch13* with other parts of the genome {#s2-4}
--------------------------------------------------

The density of *kelch13* synonymous variations in the two continents is roughly consistent with that observed in the rest of the genome (Africa: 28 SNPs/kbp, SEA: 6; [Figure 4a](#fig4){ref-type="fig"}), which is expected since synonymous changes are less likely to be affected by selection. The excess of African non-synonymous mutations in the upstream region is also consistent with expectations (Africa: 44 SNPs/kbp, SEA: 16). In contrast, non-synonymous polymorphisms in the KPBD show a reversal of this relationship: SEA parasites possess about 30% more polymorphisms than African ones (34 in SEA vs. 26 in AFR). In addition, all but two non-synonymous changes in the KPBD are observed in Africa at very low frequency (singletons and doubletons), while in SEA more than half of the changes are observed in \>2 samples ([Table 4](#tbl4){ref-type="table"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).10.7554/eLife.08714.012Figure 4.Structure of *kelch13*, positioning of mutations in Africa and Southeast Asia, and sequence conservation.(**a**) The amino acid positions of *kelch13* polymorphisms observed in Africa (red) and SEA (blue) are shown. Coloured rectangles describe the extents of the resistance domains (BTB/POZ: aa. 349--448; kelch propeller: aa. 443--721) and upstream region, with the locations of non-synonymous changes indicated above, and that of synonymous changes below. Short lines represent singleton/doubleton mutations, while longer lines represent more frequent mutations. (**b**) Conservation score across amino acid residues of *kelch13*, derived by applying a CCF53P62 matrix on alignments of the *P. falciparum* gene coding sequence with its homologues in six other *Plasmodium* species for which high-quality sequence data were available: *P. reichenowi, P. vivax, P. knowlesi, P. yoelii, P. berghei*, and *P. chabaudi* (see Materials and methods). Although the region below position 200 is less conserved, particularly in rodent species (*P. yoelii, berghei*, and *chabaudi*), there is remarkably high conservation across all species over the rest of the gene, which includes the KPBD.**DOI:** [http://dx.doi.org/10.7554/eLife.08714.012](10.7554/eLife.08714.012)10.7554/eLife.08714.013Table 4.Frequency of the non-synonymous KPBD mutations. Counts of non-synonymous mutations in the conserved propeller and BTB-POZ domains of *kelch13* are shown for each geographical region, stratified by the number of samples in which they are observed. Sample size for each population is reported.**DOI:** [http://dx.doi.org/10.7554/eLife.08714.013](10.7554/eLife.08714.013)AFR\
(N = 1,648)SEA\
(N = 1,599)SAS\
(N = 75)OCE\
(N = 62)SAM\
(N = 27)1--2 samples24131103--5 samples17000\>5 samples114000

At a first approximation, these observations are consistent with a high number of non-synonymous changes that have risen in frequency in SEA parasites because of their association with artemisinin resistance, and a low number of mostly rare alleles in Africa, where artemisinin has been introduced more recently and resistance is yet to be reported.

Comparing *kelch13* to other highly conserved genes {#s2-5}
---------------------------------------------------

Although the function of *kelch13* is as yet unclear, an alignment of its homologous gene sequences in eight *Plasmodium* species shows that the propeller and BTB-POZ domains are part of a highly conserved region ([Figure 4b](#fig4){ref-type="fig"}), suggesting a crucial role in parasite fitness. A reconstruction of ancestral alleles from this alignment suggests that *P. falciparum* accumulated only five conservative amino acid changes in the *kelch13 propeller* domain since diverging from other species 55 Myr ago ([@bib11]) ([Table 5](#tbl5){ref-type="table"}). Given this extreme level of conservation, non-synonymous polymorphisms may appear surprisingly numerous in the present dataset, both in SEA (n = 34) and in Africa (n = 26). Such elevated numbers may be produced by selection processes; alternatively, they may be present in a large neutrally-evolving population, in which low-frequency variations continually emerge, but can only be detected for a brief span of time before they are removed by genetic drift and/or purifying selection. The question is, then, whether neutral evolution can account for the pattern of *kelch13* mutations observed here.10.7554/eLife.08714.014Table 5.*Kelch13 propeller* domain mutations in different *Plasmodium* species. Here we report amino acid allele differences in a multiple sequence alignments of *kelch13* homologues for seven species of *Plasmodium* parasites for which high-quality sequence data were available: *P. falciparum* (Pf), *P. reichenowi* (Pr), *P. vivax* (Pv), *P. knowlesi* (Pk), *P. yoelii* (Py), *P. berghei* (Pb), and *P. chabaudi* (Pc). The species formed three groups by similarity: Laverania (Pf, Pr), primate Plasmodia (Pv, Pk) and rodent Plasmodia (Py, Pb and Pc). An allele shared by all members of two different groups was identified as a putative ancestral allele. The table shows, for each position where at least one species exhibits a difference from the others: the amino acid position in the Pf *kelch13* sequence; the putative ancestral amino acid allele; the alleles in the various species (columns with heading listing multiple species show mutations common to those species); and a substitution score of the mutation, based on a CCF53P62 substitution matrix (see Materials and methods). All substitution scores are ≥0, denoting conservative substitutions.**DOI:** [http://dx.doi.org/10.7554/eLife.08714.014](10.7554/eLife.08714.014)Pf PositionAncestral AllelePf,PrPv,PkPkPy,Pb,PcPy,PbPbPcSubstitution Score434F\-\-\-\-\--Y2447C\-\-\--S\--1448I-M\-\-\-\--2517TV\-\-\-\-\--0519FY\-\-\-\-\--2520V\-\--L\-\--0534V\-\--I\-\--2550S\--C\-\-\--1566V\-\--I\-\--2568V-I\-\-\-\--2578A-S\-\-\-\--0584D\--E\-\-\--1590I\-\-\--V\--2593T\-\--A\-\--0605DE\-\-\-\-\--1613Q\-\-\--N-K0648D\-\--E\-\--1666V\-\--I\-\--2676A\-\--T\-\--0691DE\-\-\-\-\--1708IL\-\-\-\-\--0711S\-\-\-\--P-0723I\-\--V\-\--2

To answer this question, we compared patterns of *kelch13* mutations to those in the rest of the *P. falciparum* genome Supplementary file 1 . Since fewer non-synonymous mutations are expected in more conserved genes, we applied *genomic calibration*, i.e. we stratified these analyses by evolutionary conservation. Each gene was assigned a *conservation score* determined from a sequence alignment of the *P. falciparum* gene with its *P. chabaudi* homologue, using a substitution matrix corrected for the AT bias in the *Pf* genome ([@bib6]). *P. chabaudi* was chosen since it was the member of the group most differentiated from *P. falciparum* (rodent plasmodia) with the most complete reference sequence. A genome-wide non-linear negative correlation between gene conservation and N/S ratio is clearly observable; this trend is almost identical in the two populations ([Figure 5a](#fig5){ref-type="fig"}). Although *kelch13* did not diverge significantly from this relationship in Africa (P = 0.2), its N/S ratio in SEA was the highest observed at its level of conservation, far exceeding the expected ratio (P\<0.001). Accordingly, *kelch13* showed the most significant difference in N/S ratios between Africa and SEA genome-wide (3.7-fold, P = 2 × 10^-4^ by Fisher's exact test, [Figure 5b](#fig5){ref-type="fig"} and Supplementary file 1), even compared to other well-known drug resistance genes ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Such unusually high N/S ratio in SEA parasites is mainly due to an excess of high frequency non-synonymous variations ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}), suggesting that multiple independent origins of artemisinin resistance ([@bib35]; [@bib47]) have produced an unusually large number of common non-synonymous mutations.10.7554/eLife.08714.015Figure 5.Genome-wide analysis of N/S ratio.(**a**) For each gene with more than 2 synonymous or non-synonymous SNPs, the N/S ratio in Africa (red points) and in SEA (blue points) are plotted against the conservation score of the gene coding sequence. The *kelch13* gene values are represented by larger circles. For each region, a solid line show median values, while dotted lines delimit 95% of the genes at varying levels of conservation. This plot is truncated on the y-axis to show more clearly the bulk of the distribution; the full range is shown in [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}. (**b**) Histogram showing the distribution of the ratio of N/S ratios in SEA and Africa, for all genes with ≥5 synonymous and ≥5 non-synonymous SNPs on each region. An arrow shows the placement of *kelch13*.**DOI:** [http://dx.doi.org/10.7554/eLife.08714.015](10.7554/eLife.08714.015)10.7554/eLife.08714.016Figure 5---figure supplement 1.N/S ratio of well-known drug resistance genes.This figure shows the same data as [Figure 5a](#fig5){ref-type="fig"}, extended by mapping genes known to have undergone selection for antimalarial resistance. For each gene, we show circles marking the N/S ration in Africa (red letter) and SEA (blue letter), paired by a vertical line annotated with a p-value (by Fisher's exact test) that the two ratios are significantly different. The genes shown are *kelch13* (denoted by the letter 'K'), *pfcrt* (chloroquine resistance, 'C'), *pfdhfr* (pyrimethamine resistance, 'R'), *pfdhps* (sulfadoxine resistance, 'S'), and *pfmdr1* (resistance to chloroquine and other drugs, 'M'). These results are best analyzed in the context of the underlying selective sweeps. For example, the small difference between ratios for the *pfmdr1* gene can be explained by the association of the drug resistance phenotype with gene amplification, rather than with non-synonymous changes. Also, the extremely high N/S ratio for *pfcrt* in SEA is largely due to a paucity of synonymous SNPs, caused by the near-fixation of a very small number of haplotypes in the SEA region, yielding a p-value comparable to that of *kelch13*.**DOI:** [http://dx.doi.org/10.7554/eLife.08714.016](10.7554/eLife.08714.016)10.7554/eLife.08714.017Figure 5---figure supplement 2.Genome-wide analysis of high-frequency SNP density.(**a**) Plot of the density of frequent (present in 3 or more samples) non-synonymous mutations in Africa (red) and SEA (blue) against conservation, for all genes with more than 2 synonymous or non-synonymous SNPs, showing that *kelch13* (larger circle) is consistent with other similarly conserved genes in Africa, but has excess non-synonymous polymorphisms in SEA. (**b**) An analogous plot for synonymous mutations also shows that *kelch13* follows the normal trend among genes in Africa, but has far fewer SNPs than expected in SEA.**DOI:** [http://dx.doi.org/10.7554/eLife.08714.017](10.7554/eLife.08714.017)

From this analysis we conclude that the high prevalence of *kelch13* non-synonymous variants in SEA is not explainable by neutral evolution, but is consistent with selection of artemisinin-resistance alleles. In Africa, on the other hand, the observed non-synonymous changes appear to constitute a "physiological" level of variation consistent with a population rich in low-frequency alleles.

In Southeast Asia there are more radical substitutions in *kelch13* {#s2-6}
-------------------------------------------------------------------

The different *kelch13* mutation repertoires in Africa and in SEA raise the question of whether these sets of mutations have different structural and functional properties. While there is high conservation across the whole of the propeller domain, it is unlikely that all possible amino acid changes have the same functional relevance or that they all carry the same fitness cost for parasites. Although direct measures of functional relevance are not yet available, and the exact function of *kelch13* is hitherto unknown, we can make statistical comparisons of some properties of the observed changes, in at least two respects. First, assuming that *kelch13* function is conserved across *Plasmodium* species, we can assess the strength of evolutionary constraints at any given position by examining whether amino acid substitutions between species are conservative or radical. Second, given that *kelch* proteins have been shown in other organisms to play an adapter role, with key binding sites defined by the arrangement of hydrophobic β-strands in the propeller domain ([@bib1]), we can assess changes in hydrophobicity caused by the observed mutations, which may be informative of their functional importance.

Detailed mapping against the secondary structure of the propeller domain suggests that the polymorphisms found in SEA parasites occur in different blades, preferentially at positions proximal to the first and second β-strand of the propeller's blades ([Figure 6](#fig6){ref-type="fig"}). This may indicate that these two strands play a role in defining the binding interface to the *PI3K* protein involved in artemisinin resistance ([@bib32]), but this needs to be confirmed by in-depth structural analyses.10.7554/eLife.08714.018Figure 6.Structure of the *kelch13* propeller domain, showing the position of mutations in Southeast Asia and Africa.The sequence of the *kelch13* propeller domain (amino acids 443--726) is organized according to its 6-blade tertiary structure, with the four β-strands characterizing each blade highlighted in colour. Polymorphisms observed in SEA (top panel) and Africa (bottom panel) are shown by circles above the mutated position. Small circles indicate very rare mutations (singletons and doubletons), while larger circles are used for more frequent mutations.**DOI:** [http://dx.doi.org/10.7554/eLife.08714.018](10.7554/eLife.08714.018)10.7554/eLife.08714.019Figure 6---figure supplement 1.Characterization of *kelch13* mutations in Africa and Southeast Asia.In these plots, all *kelch13* amino acids in the propeller domains, downstream of position 430, are plotted against their Kyte-Doolittle hydrophobicity score (KD, gray). Circle symbols in plot (**a**) derived amino acid alleles in *P. falciparum*, coloured according to the conservation score against the ancestral allele ([Table 5](#tbl5){ref-type="table"}), derived from the CFF53P62 substitution matrix; lower values indicate more radical substitutions. The remaining plots use the same colouring scheme to show polymorphisms observed in ≥3 samples in Africa (**b**) or in SEA (**c**).**DOI:** [http://dx.doi.org/10.7554/eLife.08714.019](10.7554/eLife.08714.019)

We characterized changes in the propeller domain by a conservation score derived from a substitution matrix specific to AT-rich genomes ([@bib6]), and assigned a hydrophobicity score to each site, estimated from the Kyte-Doolittle (KD) hydropathicity score ([@bib26]). The five putative derived alleles that have become established in the *P. falciparum kelch13 propeller* domain since its divergence from other *Plasmodia* are all conservative changes at hydrophilic sites ([Figure 6---figure supplement 1a](#fig6s1){ref-type="fig"}). Common mutations in Africa have characteristics broadly consistent with this conservative history of change ([Figure 6---figure supplement 1b](#fig6s1){ref-type="fig"} and [Table 6](#tbl6){ref-type="table"}). Polymorphisms in SEA parasites, on the other hand, show a pattern of changes that are more radical than those in Africa (P = 10^--3^) and more commonly found at hydrophobic sites ([Figure 6---figure supplement 1c](#fig6s1){ref-type="fig"} and [Table 6](#tbl6){ref-type="table"}).10.7554/eLife.08714.020Table 6.Conservation score of KPBD mutations.The table shows, for each non-synonymous *KPBD* mutation observed in the dataset, the number of samples carrying the mutation in Africa (AFR), in Southeast Asia (SEA), and a substitution score of the mutation, based on a CCF53P62 substitution matrix; lower values indicate more radical substitutions. Mutations observed in Africa tend to have higher conservation score, whereas in SEA mutations tend to be more radical.**DOI:** [http://dx.doi.org/10.7554/eLife.08714.020](10.7554/eLife.08714.020)MutationAFRSEACFF53P62Q613E512Y630F212V637I202V589I202T573S202Y493H1762I416V112T593S102V520I102I416M102F395Y012S522C211E612D101C532S101R575K031A578S1800A676S230V534L200R561H1240A675V1180H719N180P527H150A557S100R539T0630I543T0340G449A070F446I070A481V040F673I030P667A020F614L010S485N010P443S010C580Y2423-2D353Y04-2K438N01-2P553L224-3P441L027-3G538V019-3P574L012-3V568G06-3P667L02-3S459L22-4N537I11-4Q613L10-4D584V03-5

Taken together, the above results suggest that the propeller domain has long been under very strong evolutionary constraints, and that the number and nature of the changes observed in African parasites is consistent with these constraints, once we discard the abundant rare alleles expected in such a large population. In contrast, mutations in SEA parasites are not only far more numerous than expected, but they produce radical changes that are likely to be important determinants of the binding properties of the *kelch13* protein, consistent with recent findings that binding of *kelch13* to the *PI3K* protein is a critical factor in *P. falciparum* response to artemisinin ([@bib32]).

Genetic background {#s2-7}
------------------

A recent study has shown that resistance-causing KPBD mutations are significantly more likely to arise in parasites with a particular genetic background ([@bib35]). This predisposing genetic background is marked by specific SNP alleles of the genes encoding ferredoxin (*fd*), apicoplast ribosomal protein S10 (*arps10*), multidrug resistance protein 2 (*mdr2*) and chloroquine resistance transporter (*crt*). Here we extend this analysis, confirming that this particular combination of variants is extremely common in the parts of Southeast Asia where artemisinin resistance is known to be established, and is absent from Africa and other regions sampled here ([Table 7](#tbl7){ref-type="table"}).10.7554/eLife.08714.021Table 7.Frequency of the genetic background alleles across the world. Frequency of the four genetic background alleles identified in [@bib35] for each geographical region. For each SNP, we show mutation name; chromosome number; nucleotide position; and frequencies of the mutant allele in the various populations.**DOI:** [http://dx.doi.org/10.7554/eLife.08714.021](10.7554/eLife.08714.021)MutationChrPosAFRSASSEAPNGSAMarps10-V127M1424810700.0%0.0%59.4%0.0%0.0%fd-D193Y137483950.1%2.2%62.8%23.9%0.0%mdr2-T484I1419562250.1%5.7%64.2%0.4%0.0%crt-N326S74053620.8%28.2%68.6%0.1%0.0%

Discussion {#s3}
==========

This study demonstrates the value of genomic data in characterising the current epidemic of artemisinin resistance, which is problematic for conventional molecular epidemiology since new resistance-causing mutations are continually emerging on different haplotypic backgrounds. A key problem is to define the geographical origin of KBPD mutations, and we show that this can be solved by using genomic epidemiological data to analyse ancestral relationships between samples, thereby demonstrating that the KPBD mutations observed in Africa are of local origin.

Another important question is whether KPBD mutations are under positive selection in Africa, which is difficult to determine by standard haplotype-based methods because so many independent mutations are involved. This question is further complicated by marked geographical variation in normal levels of genetic diversity, i.e. there are many more rare variants in Africa than Southeast Asia, most likely due to the larger population size and other demographic factors ([@bib31]). Here we address this question by comparing *kelch13* against other genes in the same samples, a process that we refer to as genomic calibration. We show that for most genes the ratio of non-synonymous to synonymous mutations is relatively constant across geographical regions, despite geographic differences in genetic diversity, and that this ratio is correlated with the level of sequence conservation across different *Plasmodium* species. When calibrated against other genes with the same level of cross-species conservation, allowing for geographical differences in the overall level of genetic diversity, *kelch13* shows a marked excess of non-synonymous substitutions in Southeast Asia, but appears normal in Africa. Moreover, KPBD mutations causing radical amino acid changes at highly conserved positions are found at relatively high frequency in Southeast Asia but remain at very low frequency in Africa. Taken together, these findings indicate that non-synonymous KBPD mutations are undergoing strong evolutionary selection in Southeast Asia, whereas those seen in Africa have originated locally and most likely reflect normal variation.

These findings have practical implications for the prevention of artemisinin resistance in Africa, where there is evidently a deep reservoir of low frequency genetic variations that could potentially allow resistance to emerge rapidly as the levels of selective pressure increase. In most parts of Africa, the selective pressure of artemisinin is probably relatively low at present, for several reasons. Artemisinin has been widely used in Southeast Asia for over two decades, whereas its usage in Africa is more recent, and it is estimated that only 20% of infected African children currently have access to frontline treatment ACT medication ([@bib53]). Another factor is that people living in regions of high malaria endemicity acquire partial immunity, resulting in asymptomatic infection, so that there is a large reservoir of parasites in Africa that are not exposed to antimalarial drugs because asymptomatic individuals do not seek treatment ([@bib17]). The situation could change dramatically as malaria control efforts are intensified, and it will be vital to monitor the effects of major interventions on the emergence of resistance, particularly in African countries that have already achieved relatively low levels of malaria transmission. A key question for the future is whether parasite populations in certain locations possess genetic features that predispose to the emergence of artemisinin resistance, as suggested by the strong association of certain *fd, arps10, mdr2* and *crt* alleles with resistance-causing KPBD mutations in Southeast Asia ([@bib35]). Another concern is that growing resistance to ACT partner drugs, now emerging in Southeast Asia ([@bib45]) may spread to Africa, or evolve independently there, and lead to increased selective pressure for artemisinin resistance there.

The global spread of resistance to chloroquine and sulfadoxine-pyrimethamine was dominated by hard sweeps of specific haplotypes originating in Southeast Asia, although it is clear that there were also localised emergences ([@bib36]). Although we still know relatively little about the functional properties of different KPBD mutations, it is clear that some are more successful than others, e.g. the C580Y allele has emerged at multiple locations in Southeast Asia and Africa, and a specific C580Y haplotype is approaching fixation in large parts of Western Cambodia ([@bib35]). The high level of sequence conservation of KPBD across *Plasmodium* species indicates that mutations in these domains incur fitness costs, and this is supported by the observation that although there have been multiple independent origins of resistance-causing *kelch13* mutations, individual *kelch13* mutations appear to have limited spread, implying that there is a substantial fitness cost in the absence of sustained drug pressure. The danger is that these fitness costs may be compensated by other genetic variants, either in *kelch13* or elsewhere in the genome, and that, as a result of this continuing evolutionary process, parasites in Southeast Asia will progressively acquire higher levels of artemisinin resistance ([@bib52]) coupled with strong biological fitness and the ability to propagate across a wide range of vector species. Under these circumstances, the current soft sweep of artemisinin resistance could give way to a pervasive hard sweep with potentially disastrous consequences.

These findings demonstrate the utility of applying genomic epidemiology to identify features of parasite demography and evolution that affect how drug resistance spreads. Future strategies to combat resistance will require better understanding of the evolutionary consequences of malaria control interventions, e.g. how the selective advantage of a resistance allele is counterbalanced by its fitness cost under different control regimes and in different geographical settings. It is now possible to approach this problem prospectively, by conducting systematic spatiotemporal sampling and genome sequencing of the parasite population as an integral part of public health interventions to prevent resistance spreading.

Materials and methods {#s4}
=====================

Ethical approval {#s4-1}
----------------

All samples in this study were derived from blood samples obtained from patients with P. falciparum malaria, collected with informed consent from the patient or a parent or guardian. At each location, sample collection was approved by the appropriate local and institutional ethics committees. The following local and institutional committees that gave ethical approval for the partner studies: Comité d\'Éthique, Ministère de la Santé, Bobo-Dioulasso, Burkina Faso; Navrongo Health Research Centre Institutional Review Board, Navrongo, Ghana; Kintampo Health Research Centre Institutional Ethics Committee, Kintampo, Ghana; Noguchi Memorial Institute for Medical Research Institutional Review Committee, University of Ghana, Legon, Ghana; Ghana Health Service Ethical Review Committee, Accra, Ghana; Gambia Government/MRC Joint Ethics Committee, Banjul, The Gambia; Comité d\'Ethique National Pour la Recherche en Santé, Guinea; Ethics Committee of Faculté de Médecine, de Pharmacie et d\'Odonto-Stomatologie, University of Bamako, Bamako, Mali; Ethical Review Committee, University of Ilorin Teaching Hospital, Ilorin, Nigeria; Institutional Review Board, Faculty of Health Sciences, University of Buea, Cameroon; Comité d'Ethique, Ecole de Santé Publique, Université de Kinshasa, Ministère de l'Enseignement Superieur, Universitaire et Recherche Scientifique, D. R. Congo; Comité National d\'Ethique auprès du Ministère de la Santé Publique, Madagascar; Institutional Review Committee, Med Biotech Laboratories, Kampala, Uganda and Uganda National Council for Sciences and Technology (UNCST); College of Medicine Research Ethics Committee, University of Malawi, Blantyre, Malawi; KEMRI National Ethical Review Committee, Kenya; Medical Research Coordinating Committee of the National Institute for Medical Research, Tanzania; Ethical Review Committee, Bangladesh Medical Research Council, Bangladesh; Ethics Committee of the International Centre for Diarrheal Disease Research, Bangladesh; Institutional Ethical Review Committee, Department of Medical Research (Lower Myanmar); Ministry of Health, Government of The Republic of the Union of Myanmar; National Ethics Committee for Health Research, Ministry of Health, Phnom Penh, Cambodia; Ministry of Health National Ethics Committee For Health Research, Laos; Ethics Committee, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Ethical Committee, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam; Eijkman Institute Research Ethics Commission, Jakarta, Indonesia; Institutional Review Board, Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea; Institutional Review Board, International Center for Medical Research and Training, Cali, Colombia; Institutional Review Board, Universidad Nacional de la Amazonia Peruana, Iquitos, Peru; Human Research Ethics Committee of NT Department of Health and Families and Menzies School of Health Research, Darwin, Australia; Institutional Review Board, New York University Medical School, NY, USA; Institutional Review Board, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA; Institutional Review Board, Walter Reed Army Institute of Research, Washington DC, USA; Ethics Review Committee, World Health Organization, Geneva, Switzerland; Ethics Committee of the Faculty of Medicine, Heidelberg, Germany; Ethics Committee of the Medical University of Vienna; Ethics Committee, London School of Hygiene and Tropical Medicine, London, UK; Oxford Tropical Research Ethics Committee, Oxford, UK.

Sample preparation, sequencing and genotyping {#s4-2}
---------------------------------------------

DNA was extracted directly from blood samples taken from patients at admission time, after leukocyte depletion to minimize human DNA. Leukocyte depletion was achieved by CF11 filtration in most samples ([@bib50]), or alternatively by Lymphoprep density gradient centrifugation (Axis‐Shield, Dundee, UK) followed by Plasmodipur filtration (Euro‐Diagnostica, Malmö, Sweden) ([@bib4]) or by Plasmodipur filtration alone. Genomic DNA was extracted using the QIAamp DNA Blood Midi or Maxi Kit (Qiagen, Hilden, Germany), and quantities of human and Plasmodium DNA were determined by fluorescence analysis using a Qubit instrument (Invitrogen, Carlsbad, California) and multi-species quantitative PCR (Q‐PCR) using the Roche Lightcycler 480 II system, as described previously ([@bib31]). Samples with \>50 ng DNA and \<80% human DNA contamination were selected for sequencing on the Illumina HiSeq platform following the manufacturer's standard protocols ([@bib5]). Paired‐end sequencing reads of length 200--300 bp were obtained, generating approximately 1 Gbp of read data per sample. All short read sequence data have been deposited in the European Nucleotide Archive (<http://www.ebi.ac.uk/ena/data/search/?query=plasmodium>), and metadata will be released at the time of publication.

Polymorphism discovery, quality control and sample genotyping followed a process described elsewhere ([@bib31]). Short sequence reads from 3,411 *P. falciparum* samples included in the *MalariaGEN Plasmodium falciparum Community Project* (<http://www.malariagen.net/projects/parasite/pf>) were aligned against the *P. falciparum* 3D7 reference sequence V3 (<ftp://ftp.sanger.ac.uk/pub/pathogens/Plasmodium/falciparum/3D7/3D7.latest_version/version3/>), using the bwa program ([@bib29]) (<http://bio-bwa.sourceforge.net/>) as previously described ([@bib31]), to identify an initial global set of 4,305,957 potential SNPs. This list was then used to guide stringent re-alignment using the SNP-o-matic algorithm ([@bib30]), to reduce misalignment errors. The stringent alignments were then examined by a series of quality filters, with the aim of removing alignment artefacts and their sources. In particular, the following were removed: a) non-coding SNPs; b) SNPs where polymorphisms have extremely low support (\<10 reads in one sample); c) SNPs with more than two alleles, with the exception of loci known to be important for drug resistance, which were manually verified for artifacts; d) SNPs where coverage across samples is lower than the 25^th^ percentile and higher than the 95^th^ percentile of coverage in coding SNPs (these thresholds were determined from artifact analysis); e) SNPs located in regions of relatively low uniqueness ([@bib31]); f) SNPs where heterozygosity levels were found to be inconsistent with the heterozygosity distribution at the SNP's allele frequency; and g) SNPs where genotype could not be established in at least 70% of the samples. These analyses produced a final list of 935,601 high-quality SNPs in the 14 chromosomes of the nuclear genome, whose genotypes were used for analysis in this study.

All samples were genotyped at each high-quality SNP by a single allele, based on the number of reads observed for the two alleles at that position in the sample. At positions with fewer than 5 reads, the genotype was undetermined (no call was made). At all other positions, the sample was determined to be *heterozygous* if both alleles were each observed in more than 2 reads; otherwise, the sample was called as homozygous for the allele observed in the majority of reads. For the purposes of estimating allele frequencies and genetic distances, a within-sample allele frequency (*f~w~*) was also assigned to each valid call. For heterozygous calls, *f~w~* was estimated as ratio of non-reference read count to reference read count; homozygous calls were assigned *f~w ~*= 0 when called with the reference allele, and *f~w ~*= 1 when called with the non-reference allele.

The genotype of *kelch13* was derived from read counts at non-synonymous SNP in the KPBD using a procedure described previously ([@bib35])

Frequency estimation and clustering {#s4-3}
-----------------------------------

For a given population *P*, we estimated the *non-reference allele frequency* (*NRAF*) at a given SNP as the mean of the within-sample allele frequency (*f~w~*) for all samples in *P* which have a valid genotype at that SNP. The *minor allele frequency* (*MAF*) at is the computed as min(*NRAF*, (1 -- *NRAF*)).

To investigate the global population structure, we started by computing an *N*x*N* pairwise distance matrix, where *N* is the number of samples. Each cell of the matrix contained an estimate of genetic distance between the relevant pair of samples, obtained by summing the pairwise distance, estimated from within-sample allele frequency (*f~w~*), at each SNP in the 100 kbp window considered. When comparing a pair of samples *s*~A~ and *s*~B~ at a single SNP *i* where a genotype could be called in each sample, with within-sample allele frequencies *f~A~* and *f~B~* respectively, the distance *d~AB~* was estimated as *d~AB~* = *f~A~* (1- *f~B~*) + *f~B~*(1- *f~A~*). The genome-wide distance D~AB~ between the two samples is then calculated as

$$D_{AB} = \frac{\alpha}{n_{AB}}\sum\limits_{i}w_{i}d_{AB}$$

where *n*~AB~ is the number of SNPs where both samples could be genotyped, *w~i~* is an LD weighting factor (see below) and α is a scaling constant, equal to 70% of the number of coding positions in the genome (since our genotyping covers approximately 70% of the coding genome). The exact value of α is uninfluential towards the analyses conducted in this study. The LD weighting factor, which corrects for the cumulative contribution of physically linked polymorphisms, was computed at each SNP *i* with *MAF* ≥ 0.1 in our sample set, by considering a window of *m* SNPs (*j* = 0.. *m*) centred at *i*. For each *j*, we computed the squared correlation coefficient *r^2^~ij ~*between SNPs *i* and *j*. Ignoring positions *j* where where r^2^*~ij~* \< 0.1, the weighting *w~i~* was computed by

$$w_{i} = \frac{1}{1 + \sum_{j}~r_{ij}^{2}}$$

A neighbour-joining tree was then produced using the nj implementation in the R ape package. Principal coordinate analysis (PCoA) was performed using the same pairwise distance matrices using the Classical Multidimensional Scaling (MDS) method ([@bib16]) PCoA is a computationally efficient variant of principal component analysis (PCA) in which a pairwise distance matrix is used as input, rather than a table of genotypes. The matrix was supplied as input to the MDS algorithm, using the R language cmdscale implementation.

Conservation scoring and ancestral allele analysis {#s4-4}
--------------------------------------------------

We analyzed homologous protein sequences of *kelch13* genes for seven *Plasmodium* species for which high-quality sequence data were available: *P. falciparum, P. reichenowi, P. vivax, P. knowlesi, P. yoelii, P. berghei*, and *P. chabaudi*. The sequences were retrieved from the OrthoMCL cluster ORTHOMCL894 in GeneDB (<http://www.genedb.org/>), and a multiple alignment was obtained using ClustalW ([@bib27]) at default settings. In turn, we considered each pair alignment of *P. falciparum* with one of the remaining species, assigning a *substitution score* to each *kelch13* amino acid position, derived from the CCF53P62 substitution matrix. Although this matrix was chosen due to its suitability for AT-rich codon biases ([@bib6]), we found that use of the more commonly used BLOSUM62 matrix ([@bib18]) did not have a significant effect on the results. Finally, each amino acid position was assigned a *conservation score* for the pair alignment, equal to the mean of the substitution scores in a 9-residue window centered at that position.

To reconstruct putative *ancestral* and *derived* alleles in the propeller domain, we catalogued all polymorphic positions in the multiple sequence alignment. We organized the seven species into three groups by similarity: Laverania (*P. falciparum, P. reichenowi*), primate Plasmodia (*P. vivax, P. knowlesi*) and rodent Plasmodia (*P. yoelii, P. berghei*, and *P. chabaudi*), and observed that at each position, only one of the groups presented an allele different from that in the remaining groups. This group-specific allele was labelled as a putative *derived* allele, and the alternative allele as *ancestral*. (see [Table 5](#tbl5){ref-type="table"}). Rodent species were found to carry the highest number of derived alleles, and therefore deemed to be good comparators for genome-wide conservation scoring. *P. chabaudi* was selected as a representative species in this group, and used for subsequent comparative analyses.

We estimated a *gene conservation score* for every *P. falciparum* gene for which a *P. chabaudi* orthologue sequence could be obtained from PlasmoDB (<http://www.plasmodb.org/>). The details of the method are described elsewhere ([@bib13]). Briefly, alignments of orthologous protein sequences were performed using ClustalW ([@bib27]) at default settings, and each amino acid position was assigned a CCF53P62 substitution score (see above). The gene conservation score assigned was equal to the mean substitution score for all amino acid positions in the gene.

Hydrophobicity analysis {#s4-5}
-----------------------

Each amino acid position in the *kelch13* was assigned a *hydrophobicity score*, estimated by computing the mean of the Kyte-Doolittle index in a 14-residue window centered at the position, using the protein sequence translated from the 3D7 reference sequence.

Chromosome painting {#s4-6}
-------------------

To reconstruct the probable origin of *kelch13* flanking haplotypes in African mutants, we used *chromosome painting* ([@bib28]), a method that compares haplotypes in a sample to those in the remaining samples, and estimates probabilities that a genome fragment originates each population, by identifying individuals that share the same haplotype. For all African and SEA samples, we applied chromosome painting across the 250 kbp flanking regions on each side of the *kelch13* gene. For each sample, haplotypes surrounding genome loci (*chunks*) were assigned posterior copying probabilities with respect to all remaining samples (*unrestricted painting*). We aggregated these probabilities according to the geographical origin of the donor samples, assigning to each chunk a probability that it originates from each of the populations. For each sample, we then estimated the expected fraction of chunks copied from each population.

In this analysis, we assumed a mutation rate per base per generation of 3.9^-10^ ([@bib7]) and a uniform recombination map. Since the two populations differ substantially in effective recombination rates ([@bib38]), we assumed a conservative recombination rate of 30 kbp/cM. Effective population size was initially set to 10,000 and optimized by 10 iterations of the expectation-maximization procedure ([@bib28]). To account for the presence of heterozygous genotypes due to mixed infections, we modified the matrix of emission probabilities by introducing a novel parameter (ε, set to 10^-8^) to represent the probability of emitting a mixed call. We repeated the analysis varying this parameter set, to assess the effects of misspecification, and results were found to be very similar qualitatively (data not shown).

Data access and URLs {#s4-7}
--------------------

Illumina sequence reads have been submitted to the European Nucleotide Archive with study accessions ERP000190 ([www.ebi.ac.uk/ena/data/view/ERP000190](www.ebi.ac.uk/ena/data/view/ERP000190)) and ERP000197 ([www.ebi.ac.uk/ena/data/view/ERP000197](www.ebi.ac.uk/ena/data/view/ERP000197)). ENA accession numbers and metadata for the samples used in this paper can obtained via the MalariaGEN website, which also provides access to genotype calls on individual samples ([www.malariagen.net/resource/16](www.malariagen.net/resource/16)). Further details of all SNPs reported in this dataset including their genome coverage, mapping quality and allele frequencies in different populations, together with tools for querying the data, can be explored at [www.malariagen.net/apps/pf](www.malariagen.net/apps/pf).
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###### Table of N/S ratio and conservation per gene.

For each *P. falciparum* gene, this table lists: the systematic ID, position and description of the gene; the ortholog gene in *P. chabaudi*; the conservation score; the count of all (N)on-synonymous and (S)ynonymous mutation in Africa (AFR) and Southeast Asia (SEA); the count of the rare (i.e. present in only 1 or 2 samples) mutations; the N/S log fold-change in SEA vs AFR; the Fisher's test p-value of N/S in AFR vs SEA.

**DOI:** [http://dx.doi.org/10.7554/eLife.08714.022](10.7554/eLife.08714.022)
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The following datasets were generated:

MalariaGEN Plasmodium falciparum Community Project,2016,Sample data and catalogue of genetic variations,<http://www.malariagen.net/resource/16>,Access information stated in Web page

MalariaGEN Plasmodium falciparum Community Project,2016,Plasmodium falciparum natural genome variation,<http://www.ebi.ac.uk/ena/data/view/ERP000190>,Publicly available at European Nucleotide Archive (accession no. ERP000190)

MalariaGEN Plasmodium falciparum Community Project,2016,Plasmodium falciparum Illumina sequencing R&D,<http://www.ebi.ac.uk/ena/data/view/ERP000197>,Publicly available at the European Nucleotide Archive (accession no. ERP000197)
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Decision letter

Neher

Richard A

Reviewing editor

Max Planck Institute for Developmental Biology

,

Germany

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Genomic epidemiology of the current wave of artemisinin resistant malaria\" for peer review at *eLife*. Your submission has been favorably evaluated by Prabhat Jha (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission

Summary:

This study presents a large number of *P. falciparum* genomes that are a valuable resource for future molecular epidemiology studies. By analyzing these data, the authors demonstrate that:

1\) Artimisinin resistance mutations arose many times independently in South East Asia and are associated with drastic amino acid changes in different domains of *kelch13*;

2\) Resistance mutations in Africa arose locally;

3\) Resistance mutations in *kelch13* likely come at a substantial cost, limiting their spread.

In addition, they provide a population genomic characterization of the *P. falciparum* diversity.

Essential revisions:

1\) The study is currently focused exclusively on *kelch13* and lacks comparison to other known resistance loci. While *kelch13* is compared to the genome wide distribution of diversity, dN/dS, etc., it should be put into context of other resistance loci. It would be straightforward to repeat some of the analysis done for *kelch13* for other loci (e.g. highlight those genes in [Figure 5](#fig5){ref-type="fig"}, add trees of haplotypes surrounding these loci in analogy to [Figure 2](#fig2){ref-type="fig"}).

2\) Data availability: the malariaGEN project hosts a comprehensive website for genomic data. However, in the interest of reproducibility and reusability additional files should be provided. We would like to see metadata for all strains included in this study. Ideally, this metadata include sampling date and location, phenotype information where available, the short read archive identifier. Similarly, the source data for figures, such as tables with dN/dS values for genes in case of [Figure 5](#fig5){ref-type="fig"}, should be provided. For follow-up analysis a flat file with the genotypes of all strains at the 935,601 high confidence SNPs and their allele frequencies in the different populations would be useful. Such files should be uploaded on data Dryad, or alternatively, a clear description on how to obtain such data from malariaGEN should be given.

3\) [Figure 1: a](#fig1){ref-type="fig"} genome wide tree is a bad way to summarize diversity in a sexual population. A projection on the first two principal components could be more useful. Location, isolates with *kelch13* mutations, phenotypes could be highlighted by color, symbol, size etc. In addition, genomic differentiation could be summarized by F~ST~ or the density of private SNPs, possibly in a sliding window along the genome. *kelch13* and other resistance loci should be outliers here.

4\) Population genomic characterization: [Figure 3](#fig3){ref-type="fig"} is uninformative. Please show the complete minor allele frequency spectra, possibly on a log-log scale to improve readability at the low frequency end. Panel c is redundant with 5a. In order to interpret [Figure 2](#fig2){ref-type="fig"}, estimates of the extent of linkage disequilibrium would be welcome (why not show LD decay surrounding *kelch13* and other resistance loci in SEA and Africa and compare to genome wide average).

5\) Hydrophobicity and radical substitutions: Given that the function of *kelch13* is unknown, the emphasis on hydrophobicity as a score for mutations is not justified. In fact, mutations in SEA are found at hydrophilic and hydrophobic sites alike. The stronger signal seems to come from conservation (but note the outlier Y493H). We suggest focusing on conservation and drop the hydrophobicity discussion unless you provide convincing evidence for a causal role of hydrophobicity changes (otherwise, it could stay as a somewhat speculative supplementary figure). The description of the calculation of the conservation score needs more detail. Why did you use a 9 amino acid window for smoothing? How did you average over multiple pairwise comparisons? While substitution matrices quantify broadly the exchangeability of amino acids, they are often a rather poor guide for site specific mutation effects. Is there a way to assess site specific conservation in a broader alignment than the one used for [Table 5](#tbl5){ref-type="table"}?

6\) Resistance mutations in Africa: A more detailed analysis is required here. Please point out African strains that carry *kelch13* mutations on the tree in [Figure 2](#fig2){ref-type="fig"}, show additional trees for different haplotype length, and maybe compare African haplotypes with resistance mutations explicitly to the closest SEA haplotype and the closest African haplotype lacking *kelch13* mutations. In [Figure 2b](#fig2){ref-type="fig"}, do African isolates that cluster with the SEA ones have special properties (e.g. C580Y mutations)? In order to render the discussion of the resistance mutations observed in Africa more concrete, a supplementary file should be provided that contains their country of origin, any drug phenotype data, whether any were culture adapted, whether these were PCR resequenced to confirm the mutations, whether there were any clinical or parasitological data to indicate that these were associated with delayed clearance rates.

7\) How representative is [Figure 2b](#fig2){ref-type="fig"} showing imperfect separation between Asia and Africa? How does this depend on the size of the window used for tree building? The two African samples that fall in between the SEA and African clusters should be discussed in greater detail and additional analyses are needed to clarify whether they are admixed.

8\) The association of *fd, aprs10, mdr2,* etc. should be explicitly discussed as correlation rather than causation as no evidence is presented for the latter. Given resource limitation, the case for including these loci in routine surveillance is weak at present. The statement in the Discussion should be toned down.

10.7554/eLife.08714.030

Author response

We thank the referees for their helpful comments and interest in these data. Based on their suggestions we have made significant changes to all of the main figures. A key question was the geographical origin of *kelch13* mutations found in Africa, and we have gone back to the drawing board and reanalysed this using an entirely new method: although the overall conclusions remain the same, our new approach is less dependent on assumptions and which gives results that are clearer and easier to present. The revised manuscript also has greater clarity about the extensive data resources that underlie this analysis, including open access web application that provides user-friendly tools to explore the properties and regional allele frequencies of all of the \>900k SNPs used in this analysis, and to learn about the 31 partner studies and 43 sampling locations that contributed to this consortial project.

*Summary:*

*This study presents a large number of P. falciparum genomes that are a valuable resource for future molecular epidemiology studies. By analyzing these data, the authors demonstrate that: 1) Artimisinin resistance mutations arose many times independently in South East Asia and are associated with drastic amino acid changes in different domains of kelch13; 2) Resistance mutations in Africa arose locally;*

3\) Resistance mutations in kelch13 likely come at a substantial cost, limiting their spread.

*In addition, they provide a population genomic characterization of the P. falciparum diversity.*

The three bullet points are a good summary of our main conclusions. However it is a bit of an overstatement to add that we "provide a population genomic characterization of *P. falciparum* diversity". Although this paper does contain a lot of population genomic information, it is to provide context for our analysis of the *kelch13* locus. For a more comprehensive set of population genomic analyses on these samples, readers are referred to other outputs of the *P. falciparum* Community Project and its companion *Pf3k Project*, as outlined below.

*Essential revisions:*

*1) The study is currently focused exclusively on kelch13 and lacks comparison to other known resistance loci. While kelch13 is compared to the genome wide distribution of diversity, dN/dS, etc., it should be put into context of other resistance loci. It would be straightforward to repeat some of the analysis done for kelch13 for other loci (e.g. highlight those genes in [Figure 5](#fig5){ref-type="fig"}, add trees of haplotypes surrounding these loci in analogy to [Figure 2](#fig2){ref-type="fig"}).*

We intentionally focus on *kelch13* because of its scientific interest and practical importance. It would be fascinating to perform detailed analyses on other resistance loci, and then to compare and contrast the findings, but that is beyond the scope of the present paper. Different resistance loci have evolved over different timescales, with different demographic histories and selective processes, and each requires a focused analysis to understand what is going on. For example, detailed characterisation of the *pfcrt* locus alone would be a major undertaking, given the remarkably complex patterns of diversity that have emerged in different parts of the world following \>60 years of selective pressure.

With the caveat that such comparisons can be misleading if taken out of context, in the revised version we show N/S ratios for other major resistance loci: *pfcrt*, *pfmdr1, pfdhfr* and *pfdhps*. It can be seen that both *pfcrt* and *kelch13* have high N/S ratios in Southeast Asia, but readers need to be aware that very different processes are driving this signal for the two loci -- the former is associated with a hard sweep and extreme loss of diversity, whereas the latter is associated with a multitude of resistant haplotypes. Because of these caveats, we propose that this new figure is supplementary to [Figure 5](#fig5){ref-type="fig"}, retaining the main focus of the paper on the *kelch13* evolutionary pattern.

*2) Data availability: the malariaGEN project hosts a comprehensive website for genomic data. However, in the interest of reproducibility and reusability additional files should be provided. We would like to see metadata for all strains included in this study. Ideally, this metadata include sampling date and location, phenotype information where available, the short read archive identifier. Similarly, the source data for figures, such as tables with dN/dS values for genes in case of [Figure 5](#fig5){ref-type="fig"}, should be provided. For follow-up analysis a flat file with the genotypes of all strains at the 935,601 high confidence SNPs and their allele frequencies in the different populations would be useful. Such files should be uploaded on data Dryad, or alternatively, a clear description on how to obtain such data from malariaGEN should be given.*

We now provide additional supporting data, as summarised below, and the revised manuscript describes more clearly how to access these and other data that we have already released.

i\. We have created a resource page at <http://www.malariagen.net/resource/16> to accompany this paper, which provides links to the data release plus other information about the project. This takes the reader to a permanent URL listing all the online resources relating to this study. The revised manuscript gives links to these web resources in two places: in the introduction and in a new section entitled \'Data access and URLs\'. In addition we provide links to specific resources where appropriate in the Results and Methods sections.

ii\. We have released details of all high confidence SNPs analysed in this study, together with their regional allele frequencies, through a user-friendly web application with interactive tools for exploring and querying the data. This is now online at www.malariagen.net/apps/pf

iii\. We have released genotype calls on individual samples (i.e. 935,601 SNPs genotyped in 3,394 samples). These are made available via the Wellcome Trust Sanger Institute public ftp site and can be accessed from <http://www.malariagen.net/content/p-falciparum-community-project-jan-2016-data-release>. We are unable to openly release the sequence data from Indonesia due to national export restrictions. This involves only 17 samples, i.e. less than 1% of the total.

iv\. We provide an Excel spreadsheet containing the source data for [Figures 3](#fig3){ref-type="fig"} and 5. For each *P. falciparum* gene analyzed, this table lists: the ortholog gene in *P. chabaudi*, the conservation score, the count of non-synonymous and synonymous mutation in Africa and Southeast Asia, the log fold change and the associated p-value. We propose that this is released as a supplementary file to the paper.

v\. The sequence read data have been deposited in the European Nucleotide Archive (ENA). At the time of publication we will release a sample metadata file on [www.malariagen.net/resource/16](www.malariagen.net/resource/16). Each sample will be identified by its ENA accession number, country of origin, year of collection, and by partner study that contributed the sample.

vi\. Many of these samples are also part of the Pf3k Project whose goal is to undertake a comprehensive analysis of genome variation in 3,000 parasite samples representing the major malaria endemic regions of the world, and to make all of these data openly available. The Pf3k web application provides open access variant call data for 2,375 (68%) of the 3,488 samples included in the present study ([www.malariagen.net/apps/pf3k](www.malariagen.net/apps/pf3k)) and these data will be continually improved as new analytical methods become available.

To put the above data resources in context, the present manuscript is one output of a larger Community Project with a dual purpose: (1) to provide malaria research groups with access to genome sequencing on their samples and to enable them to incorporate these data into their own analyses; (2) to combine data across multiple partner studies to perform global analyses such as the current manuscript (<http://www.malariagen.net/projects/parasite/pf>). One of the major challenges is to develop an equitable data access policy that protects the legitimate interests of individual partner studies while encouraging global analyses and openly accessible data. The data resources described above represent our best efforts to balance these different considerations while continually looking for ways to increase the quality and quantity of data that is made openly available to the scientific community.

3\) [Figure 1: a](#fig1){ref-type="fig"} genome wide tree is a bad way to summarize diversity in a sexual population. A projection on the first two principal components could be more useful. Location, isolates with kelch13 mutations, phenotypes could be highlighted by color, symbol, size etc. In addition, genomic differentiation could be summarized by F~ST~ or the density of private SNPs, possibly in a sliding window along the genome. kelch13 and other resistance loci should be outliers here.

Unfortunately it is impossible to summarize the diversity of this population in a single graphic. Both neighbor-joining trees and PCA plots have limitations, and the most pragmatic approach is to use a variety of methods. In Figure 1---figure supplement 1 it can be seen that PC1 separates Africa and South America from the rest of the world, whereas PC2 is driven by recent founder events in Southeast Asia (see Miotto et al. 2013 for a fuller discussion). These founder effects can also be seen on the NJ tree but are much less pronounced, and we therefore felt that the NJ tree was more suitable for [Figure 1](#fig1){ref-type="fig"}, as it provides a more intuitive visualization for the average reader. However we do not feel strongly about this and are happy to include both NJT and PCA as main display items.

As suggested we have also included a sliding-window F~ST~ analysis which shows that the differentiation between Africa and SE Asia is fairly evenly distributed across the genome. At the *pfcrt* locus, for example, F~ST~ between Africa and SE Asia is relatively low, possibly reflecting the spread of chloroquine resistance haplotypes from SE Asia to Africa. Around the *kelch13* locus there is a much stronger signal but closer inspection reveals that this is not due to *kelch13* mutant haplotypes (which are diverse and present in only \~30% of SE Asian samples) but to nearby alleles that are close to fixation in SE Asia and presumably antedate the *kelch13* soft sweep (see, for example, [www.malariagen.net/apps/pf](www.malariagen.net/apps/pf)). Thus the results of sliding-window F~ST~ analysis are not as easy to interpret as the reviewer implies, and we would suggest not including this figure.

*4) Population genomic characterization: [Figure 3](#fig3){ref-type="fig"} is uninformative. Please show the complete minor allele frequency spectra, possibly on a log-log scale to improve readability at the low frequency end.*

We have replaced [Figure 3a](#fig3){ref-type="fig"} with a more detailed plot of the minor allele frequency spectra. We use a log-linear scale to highlight the large number of rare alleles in the African population.

Panel c is redundant with 5a.

These are the same data but presented somewhat differently in different contexts to assist the narrative. We are happy to make 3c a supplementary figure if the editor wishes.

In order to interpret [Figure 2](#fig2){ref-type="fig"}, estimates of the extent of linkage disequilibrium would be welcome (why not show LD decay surrounding kelch13 and other resistance loci in SEA and Africa and compare to genome wide average).

Thanks for this perceptive comment. Genome-wide levels of LD are known to differ between Africa and Southeast Asia (Manske et al.2012), and these differences are accentuated by founder effects associated with artemisinin resistance (Miotto et al. 2013). As a result of this comment and other considerations, we decided to replace [Figure 2](#fig2){ref-type="fig"} with a new method of analysis that does not assume a specific haplotype length and should therefore be more robust to variations in LD. This is described in more detail in comment 6.

*5) Hydrophobicity and radical substitutions: Given that the function of kelch13 is unknown, the emphasis on hydrophobicity as a score for mutations is not justified. In fact, mutations in SEA are found at hydrophilic and hydrophobic sites alike. The stronger signal seems to come from conservation (but note the outlier Y493H). We suggest focusing on conservation and drop the hydrophobicity discussion unless you provide convincing evidence for a causal role of hydrophobicity changes (otherwise, it could stay as a somewhat speculative supplementary figure).*

We have revised the main text to provide a clearer rationale of the potential importance of hydrophobicity. Mbengue et al. (Nature 2015) have shown that *kelch13* binds to PI3K (a target of artemisinin), marking it for degradation. Kelch binding sites in general are determined by the arrangement of hydrophobic β-strands in the propeller domain. It is therefore interesting that radical mutations at hydrophobic sites are relatively common in Southeast Asia compared to Africa, or compared to variations seen between different *Plasmodium* species.

However we are not arguing that hydrophilic changes are unimportant, and to avoid undue emphasis on hydrophobicity, we have moved what was formerly [Figure 6](#fig6){ref-type="fig"} to become a supplementary figure. In the new [Figure 6](#fig6){ref-type="fig"} (formerly Figure 7) we have created two panels to show more clearly the different structural distribution of mutations in SEA and Africa. We have also removed 7b which highlighted the periodic pattern of hydrophobicity.

The description of the calculation of the conservation score needs more detail. Why did you use a 9 amino acid window for smoothing? How did you average over multiple pairwise comparisons?

We have applied the method described by Gardner et al. (BMC Evolutionary Biology 2011), which includes a 9-amino acid smoothing window. This did not involve averaging over multiple comparisons: as stated in Results: \"Each gene was assigned a conservation score determined from a sequence alignment of the *P. falciparum* gene with its *P. chabaudi* homologue." The problem with using multiple species in the genome-wide analysis is that it greatly reduces the number of genes that can be analysed due to lack of complete reference sequences for most species. In the revised manuscript we clarify this point: "*P. chabaudi* was chosen since it was the member of the group most differentiated from *P. falciparum* (rodent plasmodia) with the most complete reference sequence.\" However for *kelch13* there are available data from multiple species, as shown in revised [Figure 4b](#fig4){ref-type="fig"}.

*While substitution matrices quantify broadly the exchangeability of amino acids, they are often a rather poor guide for site specific mutation effects. Is there a way to assess site specific conservation in a broader alignment than the one used for [Table 5](#tbl5){ref-type="table"}?*

[Table 5](#tbl5){ref-type="table"} summarizes the conservation data that we can garner from alignments that capture \~50 Mya of parasite evolution. A broader alignment would require analysis of non-Plasmodium species with very low levels of sequence identity, which we think is beyond the scope of the present work.

*6) Resistance mutations in Africa: A more detailed analysis is required here. Please point out African strains that carry kelch13 mutations on the tree in [Figure 2](#fig2){ref-type="fig"}, show additional trees for different haplotype length, and maybe compare African haplotypes with resistance mutations explicitly to the closest SEA haplotype and the closest African haplotype lacking kelch13 mutations. In [Figure 2b](#fig2){ref-type="fig"}, do African isolates that cluster with the SEA ones have special properties (e.g. C580Y mutations)? In order to render the discussion of the resistance mutations observed in Africa more concrete, a supplementary file should be provided that contains their country of origin, any drug phenotype data, whether any were culture adapted, whether these were PCR resequenced to confirm the mutations, whether there were any clinical or parasitological data to indicate that these were associated with delayed clearance rates. 7) How representative is [Figure 2b](#fig2){ref-type="fig"} showing imperfect separation between Asia and Africa? How does this depend on the size of the window used for tree building? The two African samples that fall in between the SEA and African clusters should be discussed in greater detail and additional analyses are needed to clarify whether they are admixed.*

These are insightful comments, which along with other considerations have caused us to rethink this part of our analysis. Any flanking haplotype method that relies on a specific window size (such as the trees we showed in the previous version of [Figure 2](#fig2){ref-type="fig"}) is problematic because too-large a window may mask signals of recombination close to the gene of interest, whereas too-small a window will result in lower genetic distances making the tree topology unreliable. A further problem in choosing window size (as highlighted in Comment 4) is that LD decay is difficult to estimate in SEA.

We now use an entirely different approach to determine the most likely geographic origin of *kelch13* mutations, and [Figure 2](#fig2){ref-type="fig"} has been revised accordingly. We have conducted a new analysis using *chromosome painting*, which provides a probabilistic framework to identify shared haplotypes and analyse haplotype origin. As shown in the revised version of [Figure 2](#fig2){ref-type="fig"}, based on analysis of both *kelch13* flanking regions, there are two African samples that could plausibly have common origin with Asian samples, while another four are similar to Asian samples in one of the flanking regions.

The revised manuscript has a more detailed discussion of these findings. The two African samples with Asian features in the region of *kelch13* represent only a small minority of the African samples observed to have *kelch13* mutations, and they were collected in two different countries. They are clearly separated from other African samples when analysed at the level of the whole genome ([Figure 1](#fig1){ref-type="fig"}) and to complicate matters they are also multiclonal infections. Therefore they could possibly be mixtures of African and Asian parasites, either real or due to laboratory contamination, and the present data do not allow us to confidently rule out either of these possibilities. Taken together, these findings offer no clear evidence that *kelch13* mutations have spread from Asia to Africa, but this is clearly something that will need to be kept under close surveillance in the future.

In comment 2 we clarify the available metadata which includes country of origin and year of sampling. The dataset assembled for this consortial analysis described here does not include any clinical, parasitological or phenotypic data. The samples were contributed by multiple partner studies pursuing specific research questions independently of the consortial analysis, as outlined in the accompanying web application ([www.malariagen.net/apps/pf/](www.malariagen.net/apps/pf/)). The vast majority of samples were leukocyte-depleted venous blood, sequenced without culture adaptation. We used stringent quality filters to minimize the likelihood of false positive mutations, an approach which is at least as accurate as PCR resequencing as we have reported elsewhere (Manske et al.2012). Note that many African *kelch13* mutations are found in multiclonal infections, which can be problematic for conventional PCR resequencing.

*8) The association of fd, aprs10, mdr2, etc., should be explicitly discussed as correlation rather than causation as no evidence is presented for the latter. Given resource limitation, the case for including these loci in routine surveillance is weak at present. The statement in the Discussion should be toned down.*

We have modified the Discussion as follows: "A key question for the future is whether parasite populations in certain locations possess genetic features that predispose to the emergence of artemisinin resistance, as suggested by the strong association of certain *fd, arps10, mdr2* and *crt* alleles with resistance-causing KPBD mutations in Southeast Asia."
